Parallel Advisors’s Opus Genetics IRD Stock Holding History

Parallel Advisors’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.68K	Buy	+553	New	+$2.3K	﹤0.01%	3562

Other funds holding IRD

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return

James Investment Research Alpha, Ohio $936M AUM 24.49% 1-Year Est. Return

SPAL

StoneRidge PMG Advisors, LLC Radnor, Pennsylvania $142M AUM

StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return

Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return

First City Capital Management Savannah, Georgia $204M AUM 20.28% 1-Year Est. Return

Parallel Advisors's IRD Position: Q3 2026 in Review

Parallel Advisors opened a new position in Opus Genetics (IRD) in Q3 2026: 553 shares worth $2.68K. The stake represents ﹤0.01% of the portfolio and ranks #3562 among its holdings.

23 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

Parallel Advisors held 553 shares of Opus Genetics worth $2.68K as of Q3 2026.
Opus Genetics was a new Parallel Advisors position in Q3 2026.
Opus Genetics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3562 holding.
23 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.